Cassava Sciences Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while YieldMax AI & Tech Portfolio Option Income ETF trades at $42.64 (market cap $135.69M). The key difference: YieldMax AI & Tech Portfolio Option Income ETF is far larger — about 3.4× Cassava Sciences Inc's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and YieldMax AI & Tech Portfolio Option Income ETF for 60 Days on average.
| FLNA | GPTY | |
|---|---|---|
Market Cap | $39.40M | $135.69M |
Volume | 759,018 | 97,442 |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $50.52 |
52-Week Low | $0.68 | $34.73 |
Typical Hold Time | 37 Days | 60 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →